|[Frontiers in Bioscience 2, d207-221, May 1, 1997]|
RECENT ADVANCES IN LYMPHOCYTE SIGNALING AND REGULATION|
Chun Kung and Matthew L. Thomas
Department of Pathology, HHMI, Washington University, 660 S. Euclid Avenue, St. Louis, MO 63110
Received 4/4/97; Accepted 4/24/97; On-line 5/1/97
TABLE OF CONTENTS
The antigen receptor signaling pathway in lymphocytes is vital to their development and biological function. Recent studies have shown that protein tyrosine kinases and phosphatases are essential components in this receptor signaling pathway and therefore, are critical for the development of mature and functionally competent lymphocytes. The Src kinase family of protein tyrosine kinases coordinates the early signaling events in antigen receptor signaling via phosphorylation of tyrosine-based substrates. These kinases are regulated by the concerted action of the Csk family of non-receptor protein tyrosine kinases and the protein tyrosine phosphatase, CD45. A complex set of phosphorylation and dephosphorylation events regulate protein tyrosine kinase activity. Upon antigen stimulation, Src protein tyrosine kinases in conjunction with the tyrosine kinases, ZAP-70 and Syk initiate downstream effectors leading to Ca2+ mobilization, the activation of the Ras pathway and transcriptional activation. The roles of the various adapter proteins in these pathways are now being elucidated. It is apparent that a network of phosphorylation events connect the antigen receptor to intracellular signaling pathways.
Current model for antigen receptor signaling in lymphocytes
The T cell receptor (TCR) is a multisubunit complex of eight transmembrane proteins (1-3) (Fig. 1). The antigen recognition heterodimer consists of alpha-beta subunits that are non-covalently attached to CD3 components, gamma-epsilon, delta-epsilon and a homo- or heterodimer consisting of zeta or eta chains. Zeta chain homodimers are the most prevalent. The alpha-beta dimer confers efficient receptor recognition, while the CD3 dimers and zeta chains are critical for receptor expression and signal transduction. Expression of the TCR requires a fully assembled receptor, supporting the notion that the subunits are necessary for normal T-cell function. A functionally similar receptor complex appears in B cells (Fig. 2). The B cell receptor (BCR) consists of the surface Ig (sIg), which is the antigen recognition structure, in a non-covalent complex with two disulfide bonded heterodimers, containing an Igalpha subunit and an Igbeta subunit (1-4).
Figure 1. Regulation of antigen receptor-mediated signal transduction in T cells.
Prior to TCR activation, CD45 dephosphorylates Lck and preserves it in an active state, ready for coupling to the TCR upon antigen stimulation. After TCR activation, Lck and Fyn phosphorylate the zeta chains, enabling ZAP-70 interaction and initiating the signal transduction. Noted are the signaling pathways leading to IP3 and Ras. In addition, substrates which are tyrosine phosphorylated after TCR activation are listed.
Figure 2. Regulation of antigen receptor-mediated signal transduction in B cells.
The early events of BCR signal transduction are postulated to follow a pattern similar to those for TCR signal transduction. CD45 dephosphorylates Lyn and maintains it in an active state for coupling to the BCR upon antigen stimulation. After BCR activation, Lyn phosphorylates BCR, enabling Syk interaction to initiate signal transduction. Noted are the signaling pathways leading to IP3 and Ras.
T- and B-cell activation requires stimulation of antigen receptors to initiate signal transduction via tyrosine phosphorylation (1-3). In addition, co-stimulatory proteins such as CD4, CD8 and CD28 for T cells, and CD19 and CD21 for B cells participate in the antigen recognition process. TCR engagement through either MHC antigen coupling or anti-TCR antibody crosslinking results in tyrosine phosphorylation by the Src kinases, Lck and Fyn of the immunoreceptor tyrosine-based activation motifs (ITAMs) located in the cytoplasmic domains of CD3 and zeta chains. The ITAM consensus sequence, D/EX7D/EX2YX2L/IX7YX2L/I (where X is any amino acid), is present three times in the zeta chain and once in each CD3 component. Phosphorylation of the ITAMs leads to rapid recruitment and phosphorylation of the protein tyrosine kinase, ZAP-70 which in turn interacts with signaling molecules to initiate downstream effectors for inositol 1,4,5-triphosphate (IP3) and Ras. In B cells, a similar process occurs. BCR stimulation results in the phosphorylation by Lyn, Fyn and Blk, and of the Igalpha and Igbeta subunits, followed by rapid recruitment of Syk and other downstream effectors, thereby initiating IP3 and the Ras pathway (1-4).
Recent studies have further clarified the lymphocyte signaling pathway and characterized important components governing signal transduction. In addition, significant gains have been made in describing the interactions of these components with associated molecules and their effects on cell proliferation, differentiation, function and apoptosis. This review focuses on the current roles elucidated for the Src and Syk/ZAP-70 protein tyrosine kinases and the protein tyrosine phosphatase CD45.
The Src family of protein kinases contains nine family members: Src, Blk, Yes, Yrk, Fgr, Hck, Fyn, Lyn and Lck (1). The primary structure of the Src kinases can be subdivided into several interaction domains (Fig. 3). The amino-terminal region contains a Src homology 4 (SH4) domain for myristylation, palmitylation and interactions with acidic phospholipids. Adjoining the SH4 domain is a 50-80 amino acid stretch which acts as a putative cell surface protein binding region. This is followed in order by an SH3 domain and an SH2 domain, which bind to proline-rich sequences and tyrosine phosphorylated proteins, respectively. The kinase domain adjacent to the SH2 domain contains a tyrosine autophosphorylation site, that potentiates enzymatic activation. Another tyrosine phosphorylation site, located in the carboxyl-terminus, serves a negative regulatory function. Phosphorylation of these tyrosines regulates Src kinase activity.
Figure 3. The domain structure of the Src protein tyrosine kinase family.
The domain structure of the Src kinase family is shown, with the tyrosines in the autophosphorylation site and carboxyl-terminal domain indicated. The SH2, SH3, SH4 and kinase domains are shown. Nine members of the Src family are listed.
T cells express three Src family members: Lck, Fyn and Yes. Lck interacts with the cytoplasmic tails of CD4 and CD8alpha, whereas Fyn associates with the cytoplasmic tail of CD3 chains and zeta chain (2,5,6). Upon TCR activation, Lck and Fyn initiate the phosphorylation of ITAMs on zeta chains, CD3eta, CD3gamma and CD3delta. In addition they are implicated in the phosphorylation and activation of ZAP-70 and/or Syk (6-8).
B cells express Lyn, Lck, Fyn and Blk (1, 4). Similar to TCR activation, a cascade of phosphorylation events occurs upon BCR stimulation. The Src kinases are activated and presumably phosphorylate the ITAMs on Igalpha and Igbeta, which leads to the phosphorylation of Syk.
Syk and ZAP-70 have similar primary structures that consist of two amino-terminal SH2 domains and a kinase domain linked by hinge regions (1,6,9). Antigen activation results in the recruitment of ZAP-70 and Syk to the TCR and BCR, respectively by interacting via their SH2 domains with the doubly phosphorylated ITAMs. Trans- and auto-phosphorylation by Src and/or ZAP-70/Syk increases kinase activity (6).
Activation of the immune response in lymphocytes induces various cellular events such as cytoskeletal rearrangement, gene transcription and cell proliferation. The Ras/Rho family of GTPases are important in initiating these events. These GTPases convert extracellular stimuli into intracellular signals by regulating the activities of serine/threonine kinases, known as mitogen activated protein kinases (MAPK) (10). MAPK in turn controls gene expression important for many cellular functions, including cell growth and differentiation. The MAPK family can be subdivided into three subfamilies: extracellular signal regulated kinases (ERK), stress activated protein kinases (SAPK) or c-Jun N-terminal kinases (JNK) and p38 kinase (11). The Ras family controls ERK through the serine/threonine protein kinase, Raf. The Rho family of small GTPases is responsible for regulating stress activated protein kinases, SAPK or JNK. Along with the Ras and Rho pathways, mobilization of intracellular Ca2+ is also activated during the activation of the immune response. This is achieved through the activation of phospholipase C (PLC)-gamma1 and PLC-gamma2. IP3 and diacylglycerol are formed from the hydrolysis of phosphoinositol bisphosphate (PIP2) by PLCgamma. In due course, intracellular Ca2+ mobilization results from IP3 stimulation. Concurrently, diacylglycerol activates various isoforms of protein kinase C, which gives rise to serine/threonine phosphorylation of selective substrates (3).
To transduce the signal from the membrane receptors to any of the downstream pathways requires intermediary molecules known as adapter proteins. Many of these adapter proteins contain SH2 and/or SH3 domains making them fully capable of binding and recruiting numerous proteins (2). Upon stimulation of the immune response, adapter proteins are tyrosine phosphorylated conceivably by Src kinases or ZAP-70/Syk (1,2). In the Ras pathway, putative SH2 adapter proteins such as Vav and Shc are tyrosine phosphorylated. The 46-52kDa protein, Shc binds to the adapter protein Grb2, which is constitutively associated to Sos, the guanine nucleotide exchange factor for Ras. Shc can also interact directly with the phosphorylated zeta chains of the TCR, thereby coupling TCR stimulation to the Ras pathway (12). Vav, a 95kDa guanine nucleotide exchange factor, is implicated in Rho and Ras pathways. Moreover in the Ca2+ pathway, tyrosine phosphorylation of PLC-gamma1 and PLC-gamma2 leads to enhanced lipase activity, resulting in increased formation of IP3 and diacylglycerol from PIP2, and consequently elevated intracellular Ca2+ concentration.
ZAP-70 and Syk are involved in phosphorylating components necessary in initiating the Ras signaling pathway (1,2). Vav interacts with and is phosphorylated by Syk and ZAP-70 in activated B and T cells, respectively (13). Syk interaction with Vav is dependent upon a catalytically active Syk, the SH2 domain of Vav and the phosphorylated tyrosine residues in the linker region of Syk. In addition, T cells transfected with Syk and Vav results in increased activation of the nuclear factor of activated T cells (NFAT). Hence Syk and ZAP-70 via Vav couple the antigen receptor to the Ras signaling pathway.
Additional evidence associates Vav phosphorylation in COS-7 cells with the activation of JNK and the engagement of Rac-1 activity (14,15). Rac-1 is a member of the Rho family of GTPases, which are responsible for regulating JNK. Furthermore Vav signaling through JNK is down regulated in Rac-1 dominant negative mutants, supporting a relationship between Rac-1 and Vav (15). Other studies show Vav and Rac-1 involvement in mitogenesis, the Ras pathway and NFAT related T cell responses (16-19). Since Vav has SH2 and SH3 domains, it is possible that it can recruit proteins involved in both Ras and Rho pathways and couple them to antigen receptor-associated tyrosine kinases. Further clarification of the Vav signaling pathway is required.
As noted above, Shc and Grb2 are linked in the Ras pathway. Upon BCR stimulation, Shc is tyrosine phosphorylated. B cells deficient in Lyn or Syk display a decrease in Shc phosphorylation and Grb2-Shc association is reduced (20). These findings suggest that Shc phosphorylation is dependent on Lyn and/or Syk. Immunoprecipitation studies of Shc in B cells and co-transfected COS-1 cells show that Syk associates with and phosphorylates Shc. Altogether these results point to an involvement for Syk and Lyn in coupling the antigen receptor to the Ras pathway via Shc and Grb2.
SLP-76, a 76kDa SH2 adapter protein that is tyrosine phosphorylated during T cell activation, is preferentially phosphorylated by ZAP-70, and interacts with Grb2 and PLC-gamma1 (21). Over expression of SLP-76 in T cells results in a hyperactive receptor, whereas expression of a mutant SLP-76 that cannot be phosphorylated diminishes receptor function. Furthermore, decreased phosphorylation of SLP-76 is found in T cells expressing a catalytically inactive ZAP-70. These findings imply a role for SLP-76 in antigen receptor signaling which appears to require ZAP-70, and may involve the Ras and Ca2+ pathways.
Fyn and Lyn phosphorylate c-Cbl, a 116 kDa product of a proto-oncogene, which binds to Grb2 and the p85 subunit of phosphatidylinositol 3'-kinase (PI 3-kinase) (22-25). Fyn, through its SH2 domain, associates with and tyrosine phosphorylates c-Cbl in activated T cells and IL-3 stimulated murine myeloid cells (23-25). Also in activated B cells, the phosphorylation of c-Cbl is dependent on interactions with Lyn but not Syk (25). However binding assays using GST-fusion proteins demonstrate that the SH2 domain of Fyn can bind to non-phosphorylated c-Cbl, suggesting that Fyn may also interact with c-Cbl in a phosphotyrosine-independent manner (24). These results indicate that Fyn probably binds to c-Cbl regardless of it phosphorylation state.
Although the biological function of c-Cbl is not well defined, recent findings suggest that it may play a role in the Ras signaling pathway. Antigen stimulation causes Crk, a SH2/SH3 adapter protein, to bind to tyrosine phosphorylated c-Cbl, and results in the presence of c-Cbl-Crk complexes in the membrane particulate fraction (26). These Crk complexes are formed via interactions with SH2 domains of Crk. The SH3 domains of Crk preferentially bind C3G, a nucleotide exchange factor involved in the activation of Rap, the negative regulator of the Ras pathway. These results imply that Crk proteins may be responsible for co-localizing C3G to Rap at the membrane surface. As a result, Lyn or Fyn phosphorylates c-Cbl which in turn interacts with Crk, thereby engaging Rap mediated down regulation of Ras.
Ca2+ mobilization requires PLC-gamma action on PIP2 to form IP3 However, studies on B cells deficient in tyrosine kinase show that there are possibly two pathways leading to Ca2+ mobilization (27). With activated B cells lacking Syk, PLC-gamma2 is not phosphorylated and, IP3 production and Ca2+ mobilization are absent (27). Correspondingly, activated B cells that lack Bruton's tyrosine kinase (Btk) exhibit similar characteristics (28). In contrast, for BCR activation in B cells that lack Lyn, IP3 generation remains unaffected and a slow Ca2+ mobilization occurs (27). Immuno-precipitation studies on activated B cells show that Syk is associated with PLC-gamma1 (29). Collectively, these findings point to tyrosine kinases directing two mechanisms for intracellular Ca2+ production. Syk regulates Ca2+ mobilization through PLC-gamma and IP3 production, whereas Lyn affects Ca2+ mobilization through a different route.
The activity of Src kinases is regulated by phosphorylation and dephosphorylation of specific tyrosines (1). Src kinases contain an autophosphorylation site within the kinase domain that serves to potentiate kinase activation. The carboxyl-terminal negative regulatory tyrosine when phosphorylated, interacts intramolecularly with the SH2 domain thereby decreasing kinase activity (30-32). The crystal structures of c-Src and Hck indicate that Src kinase inactivation resulting from these intramolecular interactions arises from a conformational change in the molecule (31,32). The family of non-receptor protein tyrosine kinases, which consist of Csk and Ntk, have been shown to phosphorylate the negative regulatory domain tyrosine, thereby decreasing Src kinase activity (33,34). Studies using Csk/Ntk deficient cells suggest that Csk/Ntk are required for inactivating Src kinases. Fyn and Lyn in Csk-deficient mice are constitutively activated and exhibit increased phosphorylation, suggesting that Csk is required to repress tyrosine kinase activity (35,36). Csk cannot only phosphorylate Lck and Fyn but has also been shown to phosphorylate CD45, and thus increase phosphatase activity (37).
Apart from the negative regulation by Csk/Ntk, Src kinases are positively regulated by the protein tyrosine phosphatase, CD45 which has been shown to dephosphorylate the negative regulatory domain, thus increasing the kinase activity necessary for TCR activation (1). However, CD45 may also negatively regulate Src kinases by dephosphorylating the autophosphorylation site on Src kinases (38). Yac-1 T cells deficient in CD45 exhibit Lck hyperphosphorylated at both the autophosphorylation site and negative regulatory domain, but to a higher degree at the latter. In addition, the phosphatase domain of CD45 can dephosphorylate the autophosphorylation site of active Lck in vitro. All in all, these results point to a role for CD45 in negatively and positively regulating Lck activity.
It is also possible that Lck may be regulated by sequestration as an inactivated pool within a glycolipid enriched membrane domain (39). Lck within the glycolipid enriched membrane domain has its negative regulatory domain in a hyperphosphorylated state. It is postulated that this results from the absence of CD45 which is excluded by the glycolipid enriched membrane domain.
Another protein tyrosine phosphatase that is important in the negative regulation of protein tyrosine kinase activity is SHP-1. In T cells, SHP-1 interacts through its SH2 domains with ZAP-70 and dephosphorylates ZAP-70 (40). Thymocytes from motheaten (me) mice, which have a deficiency in SHP-1, exhibit elevated tyrosine phosphorylation after TCR stimulation due to increased activation of Src kinases (41). This implies that SHP-1 may also dephosphorylate members of the Src kinase family. In B cells, SHP-1 binds to CD22 and FcgammaRIIB to negatively regulate BCR signaling (42,43). Altogether, SHP-1 is a vital negative regulator of antigen receptor mediated signaling in both B cells and T cells.
Thymocyte development occurs as a series of selection stages, where only those meeting a defined criteria pass into mature lymphocytes (44). Immature thymocytes begin as multipotent cells which do not express CD4 or CD8, and as such are designated double negative (DN) (CD4- CD8-). Upon expansion, alphabeta gene rearrangement and expression of the TCR, the thymocytes express TCR, CD4 and CD8, and enter the double positive (DP) stage. At this point they are designated CD4+ CD8+ TCRlow. The thymocytes then undergo selection for self recognition which is dependent on the avidity of the TCR for antigen presented by MHC molecules within the thymus. During the final development stage, DP thymocytes become single positive (SP) in either CD4 or CD8 with specificity for MHC class II or class I, respectively. Those that survive have undergone positive selection and are ready for maturation.
In the bone marrow, the process of B cell development comprises several stages where the preB cells are selected to develop into long-lived mature B cells (45). At the same time the B cells are screened for tolerance against autoantigens. Initially, the pro-B/preB cells undergo rearrangement in their Heavy-chain gene loci. Those that contain the proper in frame gene rearrangement undergo Light-chain gene rearrangement to form immature B cells. After further secondary Light-chain gene rearrangement and selection against autoantigens, immature B cells exit the bone marrow to become mature B cells.
To examine the biological relevance of the Src protein tyrosine kinases in lymphocyte signaling and maturation, mice expressing mutations in a Src kinase or a deficiency in Src kinases are analysed. In mice deficient in Lck, thymocytes are generally blocked at the DP stage, but a small number of single positives are found (46). However, those that do develop exhibit only partial signaling in response to TCR stimulation. In contrast, thymocytes from mice deficient in Fyn are able to mature but SP thymocytes are hyporesponsive to TCR ligation (47,48). Thus unlike Lck, Fyn contributes to TCR signaling but is not critical for thymopoiesis. For mice deficient in both Lck and Fyn, thymocyte development is blocked at the DN stage and no mature alphabeta T cells are observed in the peripheral lymphoid organs (49,50). However, there are normal numbers of natural killer cells which have normal cytolytic activity (50). In all, these results point to a possible redundancy effect of Fyn for Lck in T cell development.
Expression of a gain of function Fyn (Y528F) transgene in lck-/- mice restores DP thymocyte development and enhances the DP to SP transition of thymocytes, further supporting a redundancy between Lck and Fyn (49). However, the Fyn transgene only marginally affects RAG1-/- mice whereas expression of a constitutively active Lck restores normal DP thymocyte development (49,51). In addition, a dominant negative Fyn does not affect T cell development while a dominant negative Lck abrogates DP thymocyte development (52-54). Taken together, these results show that Fyn and Lck do not have identical functions. Nonetheless, Fyn can transduce signals required for positive selection of DP thymocytes and can subserve Lck in some aspects of T cell development.
It is apparent that Lck is required for positive selection of thymocytes. In support of this, a catalytically inactive Lck expressed in DP thymocytes unambiguously blocks positive selection (55). However, other defects present in DP thymocytes deficient in Lck can also influence positive selection. It is noted that thymocytes deficient in Lck are blocked at the DP stage and have decreased CD4 dependent signaling but relatively unaffected TCR signaling (41). In addition, these thymocytes display decreased CD5 expression and increased TCR expression. CD5, an accessory signaling molecule, is important since it negatively regulates TCR and BCR signaling, and is required for the positive selection of thymocytes (56,57). Similarly, CD4/TCR co-aggregation is essential for ZAP-70 activation in DP thymocytes (58). Hence, altered CD5 or TCR expression can affect the positive selection of DP thymocytes deficient in Lck. Nevertheless expression of the Fyn transgene (Y528F) normalizes CD5 and TCR expression (49).
Lyn is critical for BCR signal transduction and this is supported by the findings from mice deficient in Lyn (59). These mice exhibit decreased numbers of B cells, which may result from a failure in B cell expansion. It is noteworthy that the lymph nodes of mice deficient in Lyn have deformed germinal centers. B cell function is also impaired as shown by their poor response to lipopolysaccharide stimulation. However, their response to CD40 stimulation is normal. In addition, these mice exhibit elevated levels of serum IgM due to increased numbers of plasma cells producing IgM, circulating autoreactive antibodies and symptoms characteristic of an autoimmune disease. Therefore, these results demonstrate that Lyn is vital for proficient B cell signaling and establish Lyn dependence in B cell selection.
ZAP-70 and Syk are also important for lymphocyte development. A portion of humans or mice with severe combined immunodeficiency (SCID), display a defective ZAP-70 or a deficiency in ZAP-70 (60-62). The normal number of CD4+ cells are present but they are non-functional. No CD8+ thymocytes are present in the periphery. Mice deficient in ZAP-70 have a thymocyte block at CD4+ CD8+ TCRlow stage but can be rescued with human ZAP-70 (63). Deficient mice exhibit elevated numbers of normal DP thymocytes. Mice deficient in Syk exhibit normal thymopoiesis (64,65). Therefore ZAP-70 but not Syk is vital for thymocyte development. However, mice deficient in Syk have decreased numbers of mature B cells and signaling through the BCR is impaired (64-66). Furthermore, they display impaired gammadelta T cell development (67).
ZAP-70 and Syk have similar structural and functional properties, which could imply a redundancy between these two kinases. However the different expression patterns of ZAP-70 and Syk may affect their roles (68). ZAP-70 is not expressed in peripheral B cells but is restricted to T cells, natural killer cells and thymocytes. However, Syk is expressed in thymocytes and predominantly in peripheral B cells but down regulated in peripheral T cells. Recent findings attempt to address the functional overlap between ZAP-70 and Syk. In B cells deficient in Syk, the BCR is non-functional. Nonetheless, expression of ZAP-70 in these cells reconstitutes BCR signaling (69). Functionally competent SH2 and catalytic domains of ZAP-70 are essential for full BCR activity. ZAP-70, like Syk, binds to the phosphorylated Igalpha and Igbeta subunits, with affinities similar to their interactions with the CD3eta subunit. Therefore under these conditions, ZAP-70 can substitute for Syk in its role in BCR signal transduction.
CD45 is a single chain transmembrane glycoprotein with two cytoplasmic phosphatase domains, of which the second domain appears to be inactive. This protein exists in various isoforms of molecular weights 180-220kDa, as a result of alternative splicing between exons 4, 5 and 6 (or A, B and C). These exons encode for the amino-terminal extracellular O-linked glycosylated region (70-73). Thus, these alternatively spliced isoforms differ in the lengths of their extracellular domains. Furthermore, they are differentially expressed on T cell subsets and resting or activated T cells, and their expression is dependent on cell differentiation and activation. CD45 is expressed by all hematopoietic cells except mature erythrocytes and platelets.
CD45 functions to regulate Src kinase activity. Evidence for this has been obtained from T and B cells deficient in CD45. In these cells, the negative regulatory domains of Lck and Fyn are hyperphosphorylated. As a consequence antigen-mediated signal transduction is compromised (74-76). CD45 does not regulate Lck and Fyn equally. (75,77). In T cells deficient in CD45, Lck tyrosine phosphorylation increases 8-10 fold over wild type compared to a 2-3 fold increase for Fyn, despite equal expression of the Src kinases. Deletion of the SH4 domain from Lck or replacement of it with the analogous domain from Fyn results in a 5 fold increase in tyrosine phosphorylation of the negative regulatory domain (78). This suggests that there are mechanisms that mediate CD45 interaction with specific Src kinases.
In B cells, Src kinases are also regulated by CD45. Lyn is hyperphosphorylated at its negative regulatory domain and autophosphorylation site in chicken DT40 B cells deficient in CD45 (79). Accordingly, BCR signaling in these cells is severely compromised. In comparison, DT40 B cells deficient in Csk and in the resting state exhibit a constitutively activated Lyn, whose autophosphorylation site is hyperphosphorylated but its negative regulatory domain is unphosphorylated (80). This implies that dephosphorylation of the carboxyl-terminal negative regulatory domain tyrosine by CD45 is a prerequisite for Lyn activity during BCR signaling. Consequently CD45 is an important positive regulator of Lyn activity and may also participate in dephosphorylating the autophosphorylation site of Lyn.
Lck and Fyn are hyperphosphorylated at the negative regulatory domain, and exhibit hyperactivity in Yac-1 T cells deficient in CD45 (74). Phosphopeptide studies on Lck from these cells demonstrate that Lck is hyperphosphorylated at both the autophosphorylation site and the negative regulatory domain, although to a greater degree at the latter site (38). Tyrosine to phenylalanine mutations of Lck at the autophosphorylation site (Y394) and negative regulatory domain (Y505) establish that the autophosphorylation site is more dominant in affecting Lck activity. In cells expressing mutations at both Y505F and Y394F, no kinase activity is observed. Furthermore, in vitro assays using the phosphatase region of CD45 and active Lck in its native conformation demonstrates that CD45 can dephosphorylate the autophosphorylation site of Lck. Thus CD45 is responsible for dephosphorylating both regulatory phosphorylation sites on Lck (38). These findings point to CD45 as a negative and positive regulator of Src kinase activity.
The extracellular region of CD45 is modified by alternative splicing of exons 4, 5 and 6 (or A, B and C), which code for O-linked glycosylation and thus govern the amount of O-linked glycosylation present (70-73). As a result, CD45 isoforms are highly regulated and differentially expressed on the various lymphocyte subsets. Results from CD45 chimeric experiments indicate that the cytoplasmic domain of CD45 is sufficient for supporting TCR signaling (81,82). However, CD45 isoform expression has been associated with lymphocyte maturation and activation. This argues that CD45 isoforms, and in particular the extracellular domain of CD45, may influence lymphocyte function. Studies expressing the individual CD45 isoforms in transgenic mice or T cell lines demonstrate that each CD45 isoform affects TCR signaling differently (83-85). In fact, cells expressing the low molecular weight isoform of CD45 appear to be the most effective in TCR signaling.
Not only is TCR signaling affected by which CD45 isoforms are present but also the tyrosine phosphorylation pattern of intracellular proteins (86,87). Adapter proteins such as Vav and SLP-76 show differential phosphorylation and varying degrees of physical association, with higher levels of each in the presence of the largest CD45 isoform (86). The regulatory effect of the CD45 isoforms may result from selective interactions of the particular isoform with cell surface molecules.
The extracellular domain of CD45 is important in mediating interactions with other membrane surface proteins which are involved in T cell activation. CD2, a 55-60 kDa glycoprotein, is involved in T cell activation. However, signal transduction via CD2 stimulation requires CD2 interactions with other signaling molecules, such as CD3eta and zeta chain (88-90). Moreover, the protein tyrosine kinases, Lck and Fyn associate with the signaling complex formed by CD2 and zeta chain (91,92). In addition, CD45 interacts with CD2 to modulate its activation of T cells (93). Studies using CD2 chimeras with CD4, CD28 and CD58 show that CD45/CD2 complexes are primarily governed by extracellular domain interactions and to a lesser extent by cytoplasmic associations. Apparently, the cytoplasmic domain of CD2 associates mainly with the zeta chain of the TCR complex. These findings point to CD45 involvement in regulating CD2 activation of T cells.
CD4, a co-stimulatory protein, associates with Lck and is involved in the antigen recognition process. CD45 isoform studies demonstrate that low molecular weight and not high molecular weight isoforms of CD45 preferentially interact with CD4 and TCR, and this association affects antigen recognition (94). Furthermore, the interaction between CD4 and CD45 is dependent upon the external domains of the CD45 isoforms but independent of the cytoplasmic domains. These results point to CD45's role in regulating antigen receptor signaling and also CD4 function in antigen recognition. In addition, CD45 interaction with CD4 may regulate Lck function and activity.
Mice deficient in CD45 exhibit defects in T cell development and impaired B cell signaling (95-98). Two separate gene targeted mice have been described in which either exon 6 or exon 9 was replaced with a neomycin cassette (95,98). The phenotype of deficient mice developed from either targeted exon is similar. T cell development is severely inhibited at two distinct stages: development of DP thymocytes from DN thymocytes is reduced twofold and the maturation of DP in to SP is decreased fivefold. In addition, TCR induced apoptosis of thymocytes is impaired whereas non-TCR stimulated apoptosis is unaffected. Altogether, these results demonstrate that CD45 is required for T cell development and is consistent with the observation that CD45 is necessary for efficient signaling through the TCR.
Exon 6 targeted mice have normal numbers of B cells, which are responsive to lipopolysaccharrides (95,96). However, IgM stimulation fails to induce B cell proliferation. Furthermore while extracellular Ca2+ influx is abrogated, intracellular Ca2+ mobilization is normal upon anti-Ig induction. In mice with the exon 9 mutation, B cell development is unaffected but no BCR signaling is observed when stimulated by anti-IgM or anti-IgD (98). However stimulation through CD40 (anti-CD40) is unaffected compared to reduced signaling through CD38 (anti-CD38). Altogether, CD45 plays an important role in Ig mediated-BCR signaling and in some aspects of CD38 signaling. It also may be important for extracellular Ca2+ influx.
As noted above, immature B cells undergo selection during maturation to determine the competency of the BCR. In mice deficient in CD45, this selection process is altered due to changes in antigen receptor signaling (97). The threshold signal required for selection is abnormally lowered compared to wild type, eliminating B cells which normally would be selected. Clearly, the signal generated here from antigen receptor stimulation is recognized by the deficient B cell as being improper for B cell maturation. These results demonstrate that antigen signaling is a requirement for normal mature B cell accumulation and the degree of signaling regulates proper selection. Accordingly, CD45 appears to act as a positive regulator of the signaling threshold required for B cell maturation.
During lymphocyte development, the level of CD45 expression is important for antigen receptor signaling. CD45 expression is up regulated during T cell maturation particularly during the positive selection of SP thymocytes (99). CD45 levels are low on DP thymocytes but increase when cells differentiate to CD4+ or CD8+ SP, in conjunction with increased levels of TCR-CD3 complex. Consequently greater than 90% of the positively selected thymocytes display a CD45high phenotype in contrast to a CD45low phenotype for non-selected thymocytes. Similarly CD45 expression is drastically increased during the developmental period which correlates BCR up regulation with B cell maturation (99). As a result, CD45 expression during lymphocyte development is tightly regulated with those for TCR and BCR complexes.
Currently, only a limited amount of information is known about the mechanism and participants involved in the regulation of CD45 activity. Recent studies propose that CD45 activation and function could be regulated through phosphorylation by Csk, a negative regulator of Src kinase activity (37). Cotransfection of Csk and CD45 into COS-1 cells reveal that CD45 is phosphorylated on two tyrosines, and upon phosphorylation, CD45 exhibits increased phosphatase activity. Therefore, Csk may up regulate CD45 activity and down regulate Src kinase activity.
CD45 dimerization may also be involved in regulating CD45 activity. EGF receptor chimeras containing phosphatase domain of CD45 dimerize in the presence of EGF (100). Dimer formation neutralizes CD45 function and TCR activity. However, the addition of a EGF receptor with its cytoplasmic tail truncated restores both activities. These findings suggest that CD45 dimer formation can potentially regulate CD45 activity via inactivation of phosphatase activity. Moreover CD45 is related to receptor protein tyrosine phosphatase alpha (RPTPalpha). The crystal structure of the RPTPalpha membrane-proximal catalytic domain has been solved (101). The deduced structure shows that a dimer is formed from two catalytic domains, with the N-terminal region of one monomer wedged into the active site of the other monomer. This association blocks the active site of one catalytic domain, making it inaccessible to substrate. As a result dimer formation by RPTPalpha could play a role in regulating phosphatase function, and as such a similar event may also be important in regulating CD45 function.
T cell activation requires both antigen presentation and cellular adhesion with the antigen presenting cell. TCR activation concomitantly stimulates integrin-mediated cell adhesion (102). In general, cell adhesion is mediated by integrin stimulation and the formation of focal adhesions. During this process tyrosine phosphorylation of intracellular proteins occurs. Focal adhesion kinase (FAK), a protein tyrosine kinase, is phosphorylated in response to integrin cross-linking and has been implicated in the Ras-MAPK pathway (1,2). Phosphorylation of FAK provides binding sites for Src kinases, Grb2 and paxillin. Integrin stimulation and cell adhesion induce the phosphorylation of paxillin, a cytoskeletal protein involved in transducing signals to the nucleus (1,2). Both of these proteins are major components of focal adhesions.
Apart from CD45's involvement in signal transduction, CD45 is involved in regulating the phosphorylation of paxillin and FAK in B cells (87). The phosphorylation of FAK and paxillin is dependent on the presence of CD45 in both stimulated and unstimulated B cells. Apparently, stimulation of B cells decreases FAK phosphorylation. B cells deficient in CD45 exhibit no phosphorylation of either FAK or paxillin, regardless of stimulation. These results suggest an involvement for CD45 in regulating cytoskeletal functions and cell adhesion.
CD45 influences homotypic cell adhesion of T and B cells (103-105). For T cells, only activated T cells can be induced via CD45 ligation to aggregate. Antibodies to the extracellular domain of certain CD45 isoforms are able to induce homotypic adhesion, whereas others inhibit adhesion. This adhesion can be blocked using antibodies against LFA-1, ICAM-1 and ICAM-3, suggesting that LFA-1/ICAM-1 and LFA-1/ICAM-3 pathways are involved. Typically, CD45 is found to co-localize with LFA-1 at the cell-cell contacts after induction of cell aggregation via CD45 ligation. Antibodies to CD45 which block adhesion alter tyrosine phosphorylation of intracellular proteins induced by adhesion-activating antibodies to ICAM-3 or LFA-1. These results indicate that CD45 is an important component in mediating LFA-1 induced cell-cell aggregation.
CD45 also associates with CD100, a disulfide-linked dimer involved in T cell proliferation and this interaction increases during T cell activation (106). The expression pattern of CD100 is similar to that for CD45. Epitope-dependent antibody coupling of CD45 down regulates CD100 expression at the cell surface and induces shedding of a soluble 120kDa form of CD100. Homotypic adhesion of T cells stimulated by antibodies against CD45 is enhanced by antibodies against CD100. However the CD100 antibody does not induce homotypic adhesion. Therefore CD45 modulates CD100 function in cell aggregation and proliferation.
The association of CD45 with other membrane-associated proteins during cell adhesion may be mediated through CD45AP. Monomeric and dimeric forms of CD45 interact with the putative adapter protein CD45AP, a 36kDa phosphoprotein also known as the lymphocyte phosphatase associated protein (LPAP) (107-110). CD45AP expression in T and B cells correlates with that for CD45 (111). Cells deficient in CD45 show no surface expression of CD45AP although normal levels of its mRNA are present. Transfection of CD45 into these cells restores CD45AP expression. Therefore complex formation between CD45 and CD45AP prevents CD45AP from proteolytic degradation. Both molecules interact mainly through their transmembrane domains. Interestingly, the cytoplasmic domain of CD45AP is marked by a putative WW domain, which functionally resembles SH3 domains and may bind proline rich sequences (112). As a result, CD45AP can potentially act as an adapter protein for CD45 substrates.
Research in our laboratory is supported by the United States Public Heatlh Service Grant # AI26363. MLT is an investigator of the Howard Hughes Medical Institute.
1. L. M. L. Chow & A. Veillette: The Src and Csk families of tyrosine protein kinases in hemopoietic cells. Semin Immunol 7, 207-226 (1995)
2. G. Zenner, J. D. zur Hansen, P. Burn & T. Mustelin: Towards unraveling the complexity of T cell signal transduction. BioEssays 17, 967-975 (1995)
3. M. Szamel & K. Resch: T-cell antigen receptor-induced signal-transduction pathways - activation and function of protein kinases C in T lymphocytes. Eur J Biochem 228, 1-15 (1995)
4. L. B. Justement, V. K. Brown & J. Lin: Regulation of B cell activation by CD45: a question of mechanism. Immunol Today 15, 399-406 (1994)
5. A. Weiss & D. R. Littman: Signal transduction by lymphocyte antigen receptors. Cell 76, 263-274 (1994)
6. A. C. Chan & A. S. Shaw: Regulation of antigen receptor signal transduction by protein tyrosine kinases. Curr Opin Immunol 8, 394-401 (1995)
7. R. L. Wange, R. Guitan, N. Isakov, J. D. Watts, R. Aebersold & L. E. Samelson: Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70. J Biol Chem 270, 18730-18733 (1995)
8. A. C. Chan, M. Dalton, R. Johnson, G. H. Kong, T. Wang, R. Thoma & T. Kunoshi: Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J 14, 2499-2508 (1995)
9. D. Mege, V. Di Bartolo, V. Germain, L. Tuosto, F. Michel & O. Acuto: Mutation of tyrosines 492/493 in the kinase domain of ZAP-70 affects multiple T-cell receptor signaling pathways. J Biol Chem 271, 32644-32652 (1996)
10. E. Cano & L. C. Mahadevan: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20, 117-122 (1995)
11. C. J. Marshall: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995)
12. K. S. Ravichandran, K. K. Lee, Z. Songyang, L. C. Cantley, P. Burn & S. J. Burakoff: Interaction of Shc with the zeta chain of the T cell receptor upon T cell activation. Science 262, 902-905 (1993)
13. M. Deckert, S. Tartare-Deckert, C. Couture, T. Mustelin & A. Altman: Functional and physical interactions of Syk kinases with the Vav proto-oncogene product. Immunity 5, 591-604 (1996)
14. P. Crespo, K. E. Schuebel, A. A. Ostrom, J. S. Gutkind & X. R. Bustelo: Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385, 169-172 (1997)
15. P. Crespo, X. R. Bustelo, D. S. Aaronson, O. A. Coso, M. Lopez-Barahona, M. Barbacid & J. S. Gutkind: Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene 13, 455-460 (1996)
16. R. G. Qiu, J. Chen, D. Kim, F. McCormick & M. Symons: An essential role for Rac in Ras transformation. Nature 374, 457-459 (1995)
17. R. G. Qiu, J. Chen, F. McCormick & F. Symons: A role for Rho in Ras transformation. Proc Natl Acad Sci USA 92, 11781-11785 (1995)
18. J. Wu, S. Katzov & A. Weiss: A functional T-cell receptor signaling pathway is required for p95vav activity. Mol Cell Biol 15, 4337-4346 (1995)
19. E. Genot, S. Cleverley, S. Henning & D. Cantrell: Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J 15, 3923-3933 (1996)
20. K. Nagai, M. Takata, H. Yamamura & T. Kurosaki: Tyrosine phosphorylation of Shc is mediated through Lyn and Syk in B cell receptor signaling. J Biol Chem 270, 6824-6829 (1995)
21. J. B. Wardenburg, C. Fu, J. K. Jackman, H. Flotow, S.E. Wilkinson, D.H. Williams, R. Johnson, G. Kong, A.C. Chan & P.R. Findell: Phosphorylation of SLP-76 by the ZAP-70 protein tyrosine kinase is required for T-cell receptor function. J Biol Chem 271, 19641-19644 (1996)
22. Y-C. Liu, C. Elly, W. Y. Langdon & A. Altman: Ras-dependent, Ca2+-stimulated activation of nuclear factor of activated T cells by a constitutively active Cbl mutant in T cells. J Biol Chem 272, 168-173 (1997)
23. A. Y. Tsygankov, M. Mahajan, J. E. Fincke & J. B. Bolen: Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells. J Biol Chem 271, 27130-27137 (1996)
24. S. M. Anderson, E. A. Burton & B. L. Koch: Phosphorylation of Cbl following stimulation with interleukin-3 and its association with Grb-2, Fyn and phosphatidylinositol 3-kinase. J Biol Chem 272, 739-745 (1997)
25. T. Tezuka, H. Umemori, N. Fusaki, T. Yagi, M. Takata, T. Kurosaki & T. Yamamoto: Physical and functional association of the cbl protooncogene product with an src-family protein tyrosine kinase, p53/56lyn, in the B cell antigen receptor-mediated signaling. J Exp Med 183, 675-80 (1996)
26. R. J. Ingham, D. L. Kreb, S. M. Barbazuk, C. W. Turck, H. Hirai, M. Matsuda & M. R. Gold: B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins. J Cell Biol 271, 32306-32314 (1996)
27. M. Takata, H. Sabe, A. Hata, T. Inazu, Y. Homma, T. Nukada, H. Yamamura & T. Kurosaki: Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 13, 1341-1349 (1994)
28. M. Takata & T. Kurosaki: A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med 184, 31-40 (1996)
29. A. L. Sillman & J. G. Monroe: Association of p72syk with the src homology-2 (SH2) domains of PLC gamma 1 in B lymphocytes. J Biol Chem 270, 11806-11811 (1995)
30. H. Yamaguichi & W. A. Hendrickson: Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384, 484-489 (1996)
31. F. Sicheri, I. Moarefi & J. Kuriyan: Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997)
32. W. Xu, S. C. Harrison & M. J. Eck: Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997)
33. J-F. Cloutier, L. M. Chow & A. Veilette: Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. Mol Cell Biol 15, 5937-5944 (1995)
34. L. M. Chow, C. Jarvis, Q. Hu, S. H. Nye, F. G. Gervais, A. Veilette & L. A. Matis: Ntk: a Csk-related protein-tyrosine kinase expressed in brain and T-lymphocytes. Proc Natl Acad Sci USA 91, 4975-4979 (1994)
35. A. Imamoto & P. Soriano: Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell 73, 1117-1124 (1993)
36. S. Nada, T. Yagi, H. Takeda, T. Tokunaga, H. Nakagawa, Y. Ikawa, M. Okada & S. Aizawa: Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 73, 1125-1135 (1993)
37. M. Autero, J. Saharinen, T. Pessa-Morikawa, M. Soula-Rothhut, C. Oetken, M. Gassmann, M. Bergman, K. Alitalo, P. Burn, C.G. Gahmberg & T. Mustelin: Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56csk tyrosine kinase and activates the phosphatase. Mol Cell Biol 14, 1308-1321 (1994)
38. U. D'oro, K. Sakaguichi, E. Apella & J. D. Ashwell: Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. Mol Cell Biol 16, 4996-5003 (1996)
39. W. Rodgers & J. K. Rose: Exclusion of CD45 inhibits activity of p56csk associated with glycolipid-enriched membrane domains. J Cell Biol 135, 1515-1523 (1996)
40. D. R. Plas, R. Johnson, J. T. Pingel, R. J. Matthews, M. Dalton, G. Roy, A. C. Chan & M. L. Thomas: Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272, 1173-1176 (1996)
41. U. Lorenz, K. S. Ravichandran, S. J. Burakoff & B. G. Neel: Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyper-responsiveness. Proc Natl Acad Sci USA 93, 9624-9629 (1996)
42. G. Doody, L. Justement, C. Delibrais, R. Matthews, J. Lin, M. Thomas & D. Fearon: A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269, 242-244 (1995)
43. D. D'Ambrosio, K. L. Hippen, S. A. Minskoff, I. Mellman, G. Pani, K. A. Siminovitch & J. C. Cambier: Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcgammaRIIB1. Science 268, 293-296 (1995)
44. L. A. Conroy & D. R. Alexander: The role of intracellular signaling pathways regulating thymocyte development and leukemic T cell apoptosis. Leukemia 10, 1422-1435 (1996)
45. F. Melchers, A. Rolink, U. Grawunder, T. H. Winkler, H. Karasuyama, P. Ghia & J. Andersson: Positive and negative selection events during B lymphopoiesis. Curr Opin Immunol 7, 214-227 (1995)
46. T. J. Molina, K. Kishihara, D. P. Siderovski, W. van Ewijk, A. Narendran, E. Timms, A. Wakeham, C. J. Paige, K. U. Hartmann, A. Veillette, D. Davidson & T. W. Mak : Profound block in thymocyte development in mice lacking p56csk. Nature 357, 161-164 (1992)
47. M. W. Appleby, J. A. Gross, M. P. Cooke, S. D. Levin, X. Qian & R. M. Perlmutter: Defective T cell receptor signaling in mice lacking the thymic isoform of p59csk. Cell 70, 751-763 (1992)
48. P. L. Stein, H-M. Lee, S. Rich & P. Soriano: pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell 70, 741-750 (1992)
49. T. Groves, P. Smiley, M. P. Cooke, K. Forbush, R. M. Perlmutter & C. J. Guidos: Fyn can partially substitute for Lck in T lymphocyte development. Immunity 5, 417-428 (1996)
50. N. S. C. van Oers, B. Lowin-Kropf, D. Finlay, K. Connolly & A. Weiss: alphabeta T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases. Immunity 5, 429-436 (1996)
51. P. Mombaerts, S. J. Anderson, R. M. Perlmutter, T. W. Mak & S. Tonegawa: An activated lck transgene promotes thymocyte development in RAG-1 mutant mice. Immunity 1, 261-267 (1994)
52. M. P. Cooke, K. M. Abraham, K. A. Forbush & R. M. Perlmutter: Regulation of T cell receptor signaling by a src family protein-tyrosine kinase (p59csk). Cell 65, 281-291 (1991)
53. S. J. Anderson, S. D. Levin & R. M. Perlmutter: Protein tyrosine kinase p56csk controls allelic exclusion of T cell receptor beta chain genes. Nature 365, 552-554 (1993)
54. S. Levin, S. Anderson, K. Forbush & R. Perlmutter: A dominant-negative transgene defines a role for p56csk in thymopoiesis. EMBO J 12, 1671-1680 (1993)
55. K. Hashimoto, S. J. Soln, S. D. Levin, T. Tada, R. M. Perlmutter & T. Nakayama: Requirement for p56csk tyrosine kinase activation in T cell receptor-mediated thymic selection. J Exp Med 184, 931-943 (1996)
56. A. K. Tarakhovsky, S. B. Kanner, J. Hombach, J. A. Ledbetter, W. Muller, N. Killeen & K. Rajewsky: A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269, 535-537 (1995)
57. G. Bikah, J. Carey, J. R. Ciallella, A. Tarakhovsky & S. Bondada: CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274, 1906-1909 (1996)
58. D. L. Wiest, J. M. Ashe, R. Abe, J. B. Bolen & A. Singer: TCR activation of ZAP-70 is impaired in CD4+ CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56csk. Immunity 4, 495-504 (1996)
59. M. L. Hibbs, D. M. Tarlinton, J. Armes, D. Grail, G. Hodgson, R. Maglitto, S. A. Stacker & A. R. Dunn: Multiple defects in the immune system of lyn-deficient mice, culminating in autoimmune disease. Cell 83, 301-311 (1995)
60. A. C. Chan, T. A. Kadlecek, M. E. Elder, A. H. Filipovich, W. L. Kuo, M. Iwashima, T. G. Parslow & A. Weiss: ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264, 1599-1601 (1994)
61. M. E. Elder, D. Lin, J. Clever, A. C. Chan, T. J. Hope, A. Weiss & T. G. Parslow: Human severe combined immnuodeficiencies are due to a defect in ZAP-70, a T cell tyrosine kinase. Science 264, 1596-1599 (1994)
62. E. Arpaia, M. Shahar, H. Dadi, A. Cohen & C. M. Roifman: Defective T cell receptor signaling and CD8+ thymic selection in humans lacking ZAP-70 kinase. Cell 76, 947-958 (1994)
63. I. Negishi, N. Motoyama, K. Nakayawa, K. Nakayama, S. Senju, S. Hatakeyama,Q. Zhang, A. C. Chan & D. Y. Loh: Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 376, 435-438 (1995)
64. M. Turner, P. J. Mee, P. S. Costello, O. Williams, A. A. Price, L. P. Duddy, M. T. Furlong, R. L. Geahlen & V. L. Tybulewicz: Perinatal lethality and blocked T cell development in mice lacking the tyrosine kinase Syk. Nature 378, 298-302 (1995)
65. A. M. Cheng, B. Rowley, W. Pao, A. Hayday, J. B. Bolen & T. Pawson: Syk tyrosine kinase required for mouse viability and B cell development. Nature 378, 303-306 (1995)
66. M. Takata, H. Sabe, H. Hata, T. Inazu, Y. Homma, T. Nukada, H.Yamamura & T. Kurosaki: Tyrosine kinase Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 13, 1341-1349 (1994)
67. C. A. Mallick-Wood, W. Pao, A. M. Cheng, J. M. Lewis, S. Kulkarni, J. B. Bolen, B. Rowley, R. E. Tigelaar , T. Pawson & A. C. Hayday: Disruption of epithelial gammadelta T cell repertoires by mutations of the Syk tyrosine kinase. Proc Natl Acad Sci USA 93, 9704-9709 (1996)
68. A. C. Chan, N. S. C. van Oers, A. Tran, L. Turka, C. L. Law, J. C. Ryan, E. A. Clark & A. Weiss: Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 152, 4758-4766 (1994)
69. G. H. Kong, J. Y. Bu, T. Kurosaki, A. S. Shaw & A. C. Chan: Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity 2, 485-492 (1995)
70. G. Roy, J. Matthews, T. Woodford-Thomas & M. L. Thomas: The function of protein tyrosine phosphatases in immune regulation. Adv Prot Phosphatases 9, 121-138 (1995)
71. M. Okumura & M. L. Thomas: Regulation of immune function by protein tyrosine phosphatases. Curr Opin Immunol 7, 312-319 (1995)
72. M. L. Thomas: Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Semin Immunol 7, 279-288 (1995)
73. J. A. R. Frearson & D Alexander: Protein tyrosine phosphatases in T-cell development, apoptosis and signaling. Immunol Today 17, 385-391 (1996)
74. C. M. Burns, K. Sakaguichi, E. Appella & J. D. Ashwell: CD45 regulation of tyrosine phosphorylation and enzyme activity of of the src family kinase. J Biol Chem 269, 13594-13600 (1994)
75. T. R. Hurley, R. Hyman & B. M. Sefton: Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphatase of the Lck, Fyn, c-Src tyrosine kinases. Mol Cell Biol 18,1651-1656 (1993)
76. E. D. McFarland, T. R. Hurley, J. Pingel, J. T. Sefton, A. Shaw & M. L. Thomas: Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor. Proc Natl Acad Sci USA 90, 1402-1406 (1993)
77. M. Sieh, J. B. Bolen & A. Weiss: CD45 specifically modulates binding of Lck to a phosphopeptide encompassing the negative regulatory tyrosine of Lck. EMBO J 12, 315-322 (1993)
78. F. G. Gervais & A. Veillette: The unique amino-terminal domain of p56csk regulates interactions with protein tyrosine phosphatases inT-lymphocytes. Mol Cell Biol 15, 2393-2401 (1995)
79. S. Yanagi, H. Sugawara, M. Kurosaki, H. Sabe, H. Yamamura & T. Kurosaki: CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J Biol Chem 271, 30487-30492 (1996)
80. A. Hata, H. Sabe, T. Kurosaki, M. Takata, & H. Hanafusa: Functional analysis of Csk in signal transduction through the B-cell antigen receptor. Mol Cell Biol 14, 7306-7313 (1994)
81. S. Volarevic, B. B. Niklinska, C. M. Burns, C H. June, A. M. Weisman & J. D. Ashwell: Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. Science 260, 541-543 (1993)
82. R. R. Hovis, J. A. Donovan, M. A. Musci, D. G. Motto, F. D. Goldman, S. E. Ross & G. A. Koretzky: Rescue of signaling by a chimeric protein containing the cytoplasmic domain of CD45. Science 260, 544-546 (1993)
83. D. Chu, C. J. Ong, P. Johnson, H-S. Teh & J. D. Marth: Specific CD45 isoforms differentially regulate T cell receptor signaling. EMBO J 13, 798-807 (1994)
84. T. J. Novak, D. Farber, D. Leitenburg, S-C. Hong, P. Johnson & K. Bottomly: Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1, 109-119 (1994)
85. D. W. Mckenney, H. Onodera, L. Gorman, T. Mimura & D. M. Rothstein: Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. J Biol Chem 270, 24949-24954 (1995)
86. H. Onodera, D. G. Motto, G. A. Koretzky & D. M. Rothstein: Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase. J Biol Chem 271, 22225-22230 (1996)
87. L. I. Pao, W. D. Bedzyk, C. Persin & J. C. Cambier: Molecular targets of CD45 in B cell antigen receptor signal transduction. J Immunol 158, 1116-1124 (1997)
88. A. D. Beyers, L. L. Spruyt & A. F. Williams: Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4 or CD8 and CD5. Proc Natl Acad Sci USA 89, 2945-2949 (1992)
89. F. D. Howard, P. Moingeon, U. Moebius, D. J. McConkey, B. Yandava, T. E. Gennert & E. L. Reinherz: The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med 176, 139-145 (1992)
90. P. Moingeon, J. L. Lucich, D. J. McConkey, F. Letourneur, B. Malissen, J. Kochan, H. C. Chang, H. R. Rodewald & E. L. Reinherz: CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc Natl Acad Sci USA 89, 1492-1496 (1992)
91. A. M. Caruso, D. W. Mason & A. D. Beyers: Physical association of the cytoplasmic domain of CD2 with the tyrosine kinases p56lck and p59fyn. Eur J Immunol 23, 2196-2201 (1993)
92. M. Gassmann, K. E. Amrein, N. A. Flint, B. Schraven & P. Burn: Identification of a signaling complex involving CD2, zeta chain and p59fyn in T lymphocytes. Eur J Immunol 24, 139-144 (1994)
93. A. M. Verhagen, B. Schraven, M. Wild, R. Wallich & S. C. Meuer: Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex. Eur J Immunol 26, 2841-2849 (1996)
94. D. Leitenburg, T. J. Novak, D. Farber, B. R. Smith & K. Bottomly: The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. J Exp Med 183, 249-259 (1996)
95. T. Benatar, R. Carsetti, C. Furlonger, N. Kamalia, T. Mak & C. J. Paige: Immunoglobin-mediated signal transduction in B cells from CD45-deficient mice. J Exp Med 183, 329-334 (1996)
96. K. Kishihara, J. Penninger, V. A. Wallace et al.: Normal B lymphocyte development but impaired T cell maturation in CD45-exon 6 protein tyrosine phosphatase-deficient mice. Cell 74, 143-156 (1993)
97. J. G. Cyster, J. I. Healy, K. Kishihara, T. W. Mak, M. L. Thomas & C. C. Goodnow: Regulation of B-lymphocyte negative and positive selection by tyrosine phosphophatase CD45. Nature 381, 325-328 (1996)
98. K. F. Byth, L. A. Conroy, S. Howlett, A. J. H. Smith, J. May, D. R. Alexander & N. Holmes: CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+ CD8+ thymocytes and in B cell maturation. J Exp Med 183, 1707-1718 (1996)
99. J. Kirburg & T. Brocker: CD45 up-regulation during lymphocyte maturation. Intl Immunol 8, 1743-1749 (1996)
100. A. Takeda, J. J. Wu & A. L. Maizel: Evidence for a monomeric and dimeric forms of CD45 associated with a 30kDa phosphorylated protein. J Biol Chem 16651-16639 (1993)
101. A. M. Bilwes, J. den Hertog, T. Hunter & J. P. Noel: Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Nature 382, 555-559 (1995)
102. M. L. Dustin & T. A. Springer: T cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341, 619-624 (1989)
103. F. Spertini, A. V. Wang, T. Chatila & R. S. Geha: Engagement of the common leukocyte antigen CD45 induces homotypic adhesion of activated human T cells. J Immunol 153, 1593-1602 (1994)
104. J. M. Zapata, M. R. Campanero, M. Marazeula, F. Sanchez-Madrid & M. O. de Landazuri: B-cell homotypic adhesion through exon A restricted epitopes of CD45 involves LFA-1/ICAM-1, ICAM-3 interactions, and induces coclustering of CD45 and LFA-1. Blood 86, 1861-1872 (1995)
105. A. G. Arroyo, M. R. Campanero, P. Sanchez-Mateos, J. M. Zapata, M. A. Ursa, M. A. del Pozo & F. Sanchez-Madrid: Induction of tyrosine phosphorylation during ICAM-3 and LFA-1-mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase. J Cell Biol 126, 1277-1286 (1994)
106. C. Herold, A. Elhabazi, G. Bismuth, A. Bensussan & L. Boumsell: CD100 is associated with CD45 at the surface of human T lymphocytes- role in T cell homotypic adhesion. J Immunol 157, 5262-5268 (1996)
107. E. D. Cahir McFarland, & M. L. Thomas: CD45 protein-tyrosine phosphatase associates with the WW domain-containing protein, CD45AP, through the transmembrane region. J Biol Chem 270, 28103-28107 (1995)
108. E. Bruyns, L. R. Hendrickson-Taylor, S. Meuer, G. A. Koretzky & B. Schraven: Identification of the sites of interaction between LPAP and CD45. J Biol Chem 270, 3132-31378 (1995)
109. K. A. Kitamura, A. Maita, D. H. W. Ng, P. Johnson, A. L. Maizel & A. Takeda: Characterization of interactions between CD45 and CD45AP. J Biol Chem 270, 21151-21154 (1995)
110. D. M. Desai, J. Sap, I. Schlessinger & A. Weiss: Ligand mediated negative regulation of a chimeric transmembrane receptor tyrosine phospatase. Cell 73, 541-554 (1994)
111. B. Schraven, D. Schoenhaut, E. Bruyns, G. Koretzky, C. Eckerskorn, R. Wallich, H. Kirchgessner, P. Sakorafas, B. Labkovsky, S. Ratnofsky & S. Meuer: LPAP, a novel 32-kDa phosphoprotein that interacts with CD45 in human lymphocytes. J Biol Chem 269, 29102-29111 (1994)
112. D. C. Chan, M. T. Bedford & P. Leder: Formin binding proteins bear WWP/WW domains that bind proline-rich peptides and functionally resemble SH3 domains. EMBO J 15, 1045-1054 (1996)